This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Comorbidity management

Somavert both directly and indirectly impacts common acromegaly comorbidities

Glucose homeostasis significantly improved versus baseline1,2

-1.4 mmol/L fasting plasma glucose reduction, -0.4% HbA1c reduction versus baseline at 8 months, n=52, p≤0.0011

CV risk significantly reduced versus baseline3

Framingham Risk Score reduced from 13.9 at baseline to 11.3 at 12 months, n=62, p=0.0053

Sleep apnoea severity significantly reduced versus baseline4

Apnoea-Hypnoea index decreased from 23 at baseline to 18 at 6 months, n=12, p=0.074

Impact on aspects of glucose homeostasis of switching from octreotide LAR* to Somavert at 8 months 

Glucose homeostasis

Blood pressure

Impact on blood pressure of Somavert-mediated IGF-I normalisation at 12 months (n=62)

Framingham risk score

Impact of switching to Somavert (n=62) on Framingham Risk Score at 12 months3

Sleep apnoea

Impact on obstructive sleep apnoea (OSA) of switching to Somavert (n=12) at 6 months4

Track IGF-I, symptoms and co-morbidties with ACRODAT

Professor Partha Kar, Consultant in Diabetes and Endocrinology, Portsmouth Hospital NHS Trust, discusses the impact of acromegaly and its treatments on glycaemic control and diabetes

Learn more

Treatment impact on diabetes

Professor Partha Kar, Consultant in Diabetes and Endocrinology, Portsmouth Hospital NHS Trust, discusses the impact of acromegaly and its treatments on glycaemic control and diabetes

Explore more webinars

Acromegaly co-morbidities webinars

Watch and listen to our Rare Disease Insight series where expert speakers take a deep dive into the co-morbidities associated with Acromegaly

Watch the webinars here

Explore more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits 

Contact us

22 years experience with Somavert

Professor AJ van der Lely, Erasmus MC, Rotterdam, Netherlands, discussed the history of clinical experience with Somavert and the latest data from ACROSTUDY, a global post-marketing surveillance study

Explore more webinars

References

1. Barkan AL, et al. Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to Pegvisomant. J Clin Endocrinol Metab 2005;90(1):5684-91.
2. Drake et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003;149(6):521-7. 
3. Berg C et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 2021;95(8):3648-56.
4. Berg C, et al. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with acromegaly. Eur J Endocrinol 2009;161:829-35
5. Sandostatin
®LAR® Summary of Product Characteristics. Available here
6. Pasireotide Summary of Product Characteristics. Available here

PP-SOM-GBR-0952. June 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No